Applying branched -DNA technology testing high -risk human papillomavirus E6/E7 mRNA in liquid-based cytology for cervical cancer screening
10.13699/j.cnki.1001-6821.2014.11.007
- VernacularTitle:支链 DNA技术检测人乳头瘤病毒外显子6／7 mRNA在宫颈癌筛查中的应用
- Author:
Rong XIE
1
;
Xiong-Wei ZHENG
;
Gang CHEN
;
Tong-Yu LIU
;
Cheng HE
;
Yu-Zhen LIN
;
Lin YANG
;
Sang LI
;
ZHANG LULU
Author Information
1. 福建医科大学教学医院 福建省肿瘤医院 妇科
- Keywords:
human papilloma virus;
branched DNA signal amplification assay;
cytology;
E6/E7 mRNA
- From:
The Chinese Journal of Clinical Pharmacology
2014;(11):1000-1001,1005
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of testing E6/E7 mRNA of high risk human papilloma virus ( HPV) for cervical cancer screening by branched DNA(bDNA)technology.Methods Branched DNA(bD-NA) technology was used to detect high-risk HPV E6/E7 mRNA and DNA directly from 335 liquid cytologic test(LCT) samples(91 samples were recognized by histopathology).Both of mRNA and DNA were detec-ted in 93 samples.The data according to cytological grades or pathology were statistically analyzed.Results The expression level of HPV E6/E7 mRNA transcripts elevated corresponding to the degree of cervical dyspla-sia.Receiver operating characteristic( ROC) curve was analyzed for pre-dicting CIN2 +, the optimal operating point value was 530.53 copies· mL-1.Conclusion bDNA technology can be used to detect HPV E6/E7 mRNA well in LCT samples.HPV E6/E7 mRNA test could be a useful tool for cervical cancer screening for its positive likelihood ratio.The copies of mRNA may be used to pool out high-risk patient in cervical cancer screening.
